MESA LABORATORIES INC (MLAB) Stock Fundamental Analysis
NASDAQ:MLAB - Nasdaq - US59064R1095 - Common Stock - Currency: USD
Taking everything into account, MLAB scores 3 out of 10 in our fundamental rating. MLAB was compared to 55 industry peers in the Life Sciences Tools & Services industry. There are concerns on the financial health of MLAB while its profitability can be described as average. MLAB is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MLAB was profitable.
MLAB had a positive operating cash flow in the past year.
MLAB had positive earnings in 4 of the past 5 years.
Each year in the past 5 years MLAB had a positive operating cash flow.
1.2 Ratios
The Return On Assets of MLAB (-57.06%) is worse than 89.09% of its industry peers.
MLAB's Return On Equity of -160.71% is on the low side compared to the rest of the industry. MLAB is outperformed by 83.64% of its industry peers.
MLAB's Return On Invested Capital of 5.09% is fine compared to the rest of the industry. MLAB outperforms 65.45% of its industry peers.
MLAB had an Average Return On Invested Capital over the past 3 years of 0.49%. This is significantly below the industry average of 12.80%.
The last Return On Invested Capital (5.09%) for MLAB is above the 3 year average (0.49%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -57.06% | ||
| ROE | -160.71% | ||
| ROIC | 5.09% |
ROA(3y)-18.83%
ROA(5y)-11.13%
ROE(3y)-58.05%
ROE(5y)-34.55%
ROIC(3y)0.49%
ROIC(5y)0.96%
1.3 Margins
The Operating Margin of MLAB (7.62%) is better than 61.82% of its industry peers.
MLAB's Operating Margin has declined in the last couple of years.
MLAB has a better Gross Margin (62.68%) than 89.09% of its industry peers.
MLAB's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.62% | ||
| PM (TTM) | N/A | ||
| GM | 62.68% |
OM growth 3Y-50.43%
OM growth 5Y-42.03%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.85%
2. Health
2.1 Basic Checks
MLAB has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
MLAB has about the same amout of shares outstanding than it did 1 year ago.
MLAB has more shares outstanding than it did 5 years ago.
MLAB has a worse debt/assets ratio than last year.
2.2 Solvency
MLAB has an Altman-Z score of 1.28. This is a bad value and indicates that MLAB is not financially healthy and even has some risk of bankruptcy.
MLAB's Altman-Z score of 1.28 is in line compared to the rest of the industry. MLAB outperforms 45.45% of its industry peers.
The Debt to FCF ratio of MLAB is 4.55, which is a neutral value as it means it would take MLAB, 4.55 years of fcf income to pay off all of its debts.
MLAB has a Debt to FCF ratio of 4.55. This is in the better half of the industry: MLAB outperforms 69.09% of its industry peers.
MLAB has a Debt/Equity ratio of 0.61. This is a neutral value indicating MLAB is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.61, MLAB is not doing good in the industry: 67.27% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 4.55 | ||
| Altman-Z | 1.28 |
ROIC/WACC0.53
WACC9.62%
2.3 Liquidity
MLAB has a Current Ratio of 0.71. This is a bad value and indicates that MLAB is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of MLAB (0.71) is worse than 96.36% of its industry peers.
A Quick Ratio of 0.53 indicates that MLAB may have some problems paying its short term obligations.
MLAB has a worse Quick ratio (0.53) than 94.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.71 | ||
| Quick Ratio | 0.53 |
3. Growth
3.1 Past
MLAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 2888.24%, which is quite impressive.
The Earnings Per Share has been growing slightly by 2.64% on average over the past years.
The Revenue has grown by 11.68% in the past year. This is quite good.
The Revenue has been growing by 15.96% on average over the past years. This is quite good.
EPS 1Y (TTM)2888.24%
EPS 3Y86.46%
EPS 5Y2.64%
EPS Q2Q%-166.15%
Revenue 1Y (TTM)11.68%
Revenue growth 3Y17.31%
Revenue growth 5Y15.96%
Sales Q2Q%17.52%
3.2 Future
Based on estimates for the next years, MLAB will show a very negative growth in Earnings Per Share. The EPS will decrease by -15.43% on average per year.
MLAB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.73% yearly.
EPS Next Y-68.8%
EPS Next 2Y7.25%
EPS Next 3Y-15.43%
EPS Next 5YN/A
Revenue Next Year13.02%
Revenue Next 2Y8.8%
Revenue Next 3Y7.73%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
MLAB is valuated rather expensively with a Price/Earnings ratio of 22.54.
Based on the Price/Earnings ratio, MLAB is valued a bit cheaper than the industry average as 74.55% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of MLAB to the average of the S&P500 Index (28.64), we can say MLAB is valued slightly cheaper.
The Price/Forward Earnings ratio is 26.48, which means the current valuation is very expensive for MLAB.
MLAB's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. MLAB is cheaper than 65.45% of the companies in the same industry.
MLAB is valuated rather expensively when we compare the Price/Forward Earnings ratio to 21.44, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.54 | ||
| Fwd PE | 26.48 |
4.2 Price Multiples
74.55% of the companies in the same industry are more expensive than MLAB, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, MLAB is valued cheaper than 92.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.46 | ||
| EV/EBITDA | 18.79 |
4.3 Compensation for Growth
A cheap valuation may be justified as MLAB's earnings are expected to decrease with -15.43% in the coming years.
PEG (NY)N/A
PEG (5Y)8.53
EPS Next 2Y7.25%
EPS Next 3Y-15.43%
5. Dividend
5.1 Amount
MLAB has a yearly dividend return of 0.57%, which is pretty low.
MLAB's Dividend Yield is rather good when compared to the industry average which is at 0.54. MLAB pays more dividend than 94.55% of the companies in the same industry.
With a Dividend Yield of 0.57, MLAB pays less dividend than the S&P500 average, which is at 2.52.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.57% |
5.2 History
The dividend of MLAB decreases each year by -0.01%.
MLAB has paid a dividend for at least 10 years, which is a reliable track record.
MLAB has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-0.01%
Div Incr Years0
Div Non Decr Years21
5.3 Sustainability
MLAB has negative earnings and hence a negative payout ratio. The dividend may be in danger.
MLAB's earnings and Dividend Rate are declining. This means the current dividend is most likely not sustainable.
DP-1.39%
EPS Next 2Y7.25%
EPS Next 3Y-15.43%
114.52
+1.48 (+1.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners95.69%
Inst Owner Change0.29%
Ins Owners4.58%
Ins Owner Change0.86%
Market Cap621.84M
Analysts78
Price Target153 (33.6%)
Short Float %4.08%
Short Ratio5.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.57% |
Yearly Dividend0.64
Dividend Growth(5Y)-0.01%
DP-1.39%
Div Incr Years0
Div Non Decr Years21
Ex-Date
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-78.88%
Min EPS beat(2)-114.45%
Max EPS beat(2)-43.31%
EPS beat(4)2
Avg EPS beat(4)795.58%
Min EPS beat(4)-114.45%
Max EPS beat(4)3254.31%
EPS beat(8)3
Avg EPS beat(8)322.16%
EPS beat(12)4
Avg EPS beat(12)200.99%
EPS beat(16)8
Avg EPS beat(16)185.92%
Revenue beat(2)1
Avg Revenue beat(2)1.4%
Min Revenue beat(2)-2.04%
Max Revenue beat(2)4.83%
Revenue beat(4)3
Avg Revenue beat(4)2.39%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)4.83%
Revenue beat(8)3
Avg Revenue beat(8)-1.1%
Revenue beat(12)5
Avg Revenue beat(12)-0.86%
Revenue beat(16)8
Avg Revenue beat(16)0.99%
PT rev (1m)0%
PT rev (3m)12.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-17.42%
EPS NY rev (1m)-81.99%
EPS NY rev (3m)-84.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.54 | ||
| Fwd PE | 26.48 | ||
| P/S | 2.62 | ||
| P/FCF | 14.46 | ||
| P/OCF | 13.22 | ||
| P/B | 4.01 | ||
| P/tB | N/A | ||
| EV/EBITDA | 18.79 |
EPS(TTM)5.08
EY4.44%
EPS(NY)4.32
Fwd EY3.78%
FCF(TTM)7.92
FCFY6.91%
OCF(TTM)8.66
OCFY7.56%
SpS43.78
BVpS28.58
TBVpS-22.12
PEG (NY)N/A
PEG (5Y)8.53
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -57.06% | ||
| ROE | -160.71% | ||
| ROCE | 6.44% | ||
| ROIC | 5.09% | ||
| ROICexc | 5.72% | ||
| ROICexgc | N/A | ||
| OM | 7.62% | ||
| PM (TTM) | N/A | ||
| GM | 62.68% | ||
| FCFM | 18.09% |
ROA(3y)-18.83%
ROA(5y)-11.13%
ROE(3y)-58.05%
ROE(5y)-34.55%
ROIC(3y)0.49%
ROIC(5y)0.96%
ROICexc(3y)0.52%
ROICexc(5y)1.37%
ROICexgc(3y)3.66%
ROICexgc(5y)11.33%
ROCE(3y)0.62%
ROCE(5y)1.22%
ROICexcg growth 3Y-57.01%
ROICexcg growth 5Y-47.53%
ROICexc growth 3Y-45.68%
ROICexc growth 5Y-46.2%
OM growth 3Y-50.43%
OM growth 5Y-42.03%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.85%
F-Score5
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 4.55 | ||
| Debt/EBITDA | 2.29 | ||
| Cap/Depr | 17.26% | ||
| Cap/Sales | 1.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.48% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.71 | ||
| Quick Ratio | 0.53 | ||
| Altman-Z | 1.28 |
F-Score5
WACC9.62%
ROIC/WACC0.53
Cap/Depr(3y)13.07%
Cap/Depr(5y)12.41%
Cap/Sales(3y)1.89%
Cap/Sales(5y)1.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2888.24%
EPS 3Y86.46%
EPS 5Y2.64%
EPS Q2Q%-166.15%
EPS Next Y-68.8%
EPS Next 2Y7.25%
EPS Next 3Y-15.43%
EPS Next 5YN/A
Revenue 1Y (TTM)11.68%
Revenue growth 3Y17.31%
Revenue growth 5Y15.96%
Sales Q2Q%17.52%
Revenue Next Year13.02%
Revenue Next 2Y8.8%
Revenue Next 3Y7.73%
Revenue Next 5YN/A
EBIT growth 1Y6885.02%
EBIT growth 3Y-41.85%
EBIT growth 5Y-32.77%
EBIT Next Year29700%
EBIT Next 3Y593.13%
EBIT Next 5YN/A
FCF growth 1Y110.16%
FCF growth 3Y5.82%
FCF growth 5Y7.25%
OCF growth 1Y89.93%
OCF growth 3Y5.99%
OCF growth 5Y7.63%